SCHEMBL24785335

SCHEMBL24785335

COc1cc(F)cc(-c2cnc(CCl)nc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.41
▸ CYP1A1 P04798 3/20 0.40
▸ CYP1B1 Q16678 3/20 0.40
▸ GRIN1 Q05586 3/20 0.39
▸ GRIN2B Q13224 3/20 0.39
▸ FGFR1 P11362 1/20 0.37
▸ FGFR2 P21802 1/20 0.37
▸ LRRK2 Q5S007 3/20 0.37
▸ GRK6 P43250 1/20 0.36
▸ PGR P06401 2/20 0.35
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2E1 P05181 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C8 P10632 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2A6 P11509 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP4B1 P13584 1/20 0.33
▸ CYP2B6 P20813 1/20 0.33
▸ CYP3A5 P20815 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103004 0.84 KDM1A (0.41) KDM1ACYP1A1CYP1B1GRIN1GRIN2B
SCHEMBL24785334 0.84 KDM1A (0.41) KDM1ACYP1A1CYP1B1GRIN1GRIN2B
SCHEMBL27859257 0.75 CYP1A1 (0.55) KDM1ACYP1A1CYP1B1LRRK2GRK6
SCHEMBL30018135 0.75 CYP1A1 (0.55) KDM1ACYP1A1CYP1B1LRRK2GRK6
SCHEMBL24785105 0.75 KDM1A (0.47) KDM1ACYP1A1CYP1B1FGFR1FGFR2
SCHEMBL30103165 0.75 KDM1A (0.47) KDM1ACYP1A1CYP1B1FGFR1FGFR2
SCHEMBL30017725 0.74 SHMT2 (0.41) GRIN1GRIN2BRAB9A
SCHEMBL1898066 0.73 CYP1A1 (0.44) KDM1ACYP1A1CYP1B1FGFR1FGFR2
SCHEMBL15263661 0.73 LMNA (0.39) CYP1A1CYP1B1NPC1RAB9A
SCHEMBL10165325 0.73 KDM1A (0.45) KDM1ACYP1A1CYP1B1GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022257960-A1 BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES 武汉人福创新药物研发中心有限公司 2022-12-15 — — WO disclosed
Send feedback